{"id":7475,"date":"2017-06-08T22:24:50","date_gmt":"2017-06-08T22:24:50","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/"},"modified":"2017-06-08T22:24:50","modified_gmt":"2017-06-08T22:24:50","slug":"nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/","title":{"rendered":"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%."},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16,34],"tags":[],"class_list":["post-7475","post","type-post","status-publish","format-standard","hentry","category-actualites-et-media","category-communiques-de-presse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-08T22:24:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%.\",\"datePublished\":\"2017-06-08T22:24:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/\"},\"wordCount\":54,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s et M\u00e9dia\",\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/\",\"name\":\"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-06-08T22:24:50+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox","og_url":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/","og_site_name":"Nicox","article_published_time":"2017-06-08T22:24:50+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/"},"author":{"name":"","@id":""},"headline":"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%.","datePublished":"2017-06-08T22:24:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/"},"wordCount":54,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s et M\u00e9dia","Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/","url":"https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/","name":"Nicox annonce l\u2019\u00e9mission et l\u2019admission aux n\u00e9gociations sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris de 597.897 actions nouvelles attribu\u00e9es aux anciens actionnaires d\u2019Aciex suite \u00e0 l\u2019approbation par la FDA am\u00e9ricaine de la demande de mise sur le march\u00e9 aux \u00c9tats-Unis du ZERVIATE (solution ophtalmique de la c\u00e9tirizine) 0,24%. - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2017-06-08T22:24:50+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-annonce-lemission-et-ladmission-aux-negociations-sur-le-marche-reglemente-deuronext-paris-de-597-897-actions-nouvelles-attribuees-aux-anciens-actionnaires-d-3\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7475"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7475\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}